Table 1.
Clinical Characteristics at Time of Baseline Stool Collection
| OSCCAR N = 184 |
|
|---|---|
| Age, Mean (Range) | 31.6 (4–83) |
| Sex, N (%) | |
| Male | 76 (41) |
| Female | 108 (59) |
| Diagnosis | |
| CD, N (%) | 115 (62) |
| Disease Location | |
| L1 – Ileal | 25 (22) |
| L2 – Colonic | 53 (46) |
| L3 - Ileocolonic | 34 (30) |
| L4a- Upper GI tract | 31 (27) |
| Disease Behavior | |
| B1 – Inflammatory | 94 (82) |
| B2 – Stricturing | 15 (13) |
| B3 – Penetrating | 6 (5) |
| Pb – Perianal | 10 (9) |
| UC, N (%) | |
| 69 (38) | |
| E1 – Proctitis | 13 (19) |
| E2 – Left sided | 22 (32) |
| E3 - Pancolitis | 34 (49) |
| Medications | |
| Corticosteroids | 81 (44) |
| Antibioticsc | 45 (25) |
| Immune Modulatorsd | 11 (6) |
| Biologics (anti-TNF α) | 6 (3) |
a
Concomitant upper tract (L4)
b
or perianal disease (P),which can be present in addition to the luminal disease distributions summarized above.
c
Antibiotics limited to metronidazole and ciprofloxacin.
d
Immune modulators include 6-mercaptopurine, azathioprine, and methotrexate.